資源描述:
《冠狀病毒Coronavirusl論文-2016 [Methods in Molecular Biology] Vaccine Design Volume 1403 __ Development of a SARS Coronavirus Vaccine from Recombi.pdf》由會員上傳分享,免費在線閱讀,更多相關內容在學術論文-天天文庫。
1、Chapter14DevelopmentofaSARSCoronavirusVaccinefromRecombinantSpikeProteinPlusDeltaInulinAdjuvantCliftonMcPherson,RichardChubet,KathyHoltz,YoshikazuHonda-Okubo,DaleBarnard,ManonCox,andNikolaiPetrovskyAbstractGivenperiodicoutbreaksoffatalhumaninfectionscausedbycoronaviruses,developmento
2、fanoptimalcoronavirusvaccineplatformcapableofrapidproductionisanongoingpriority.Thischapterdescribestheuseofaninsectcellexpressionsystemforrapidproductionofarecombinantvaccineagainstsevereacuterespiratorysyndromecoronavirus(SARS).Detailedmethodsarepresentedforexpression,puriTcation,a
3、ndreleasetestingofSARSrecombinantspikeproteinantigen,followedbyadjuvantformulationandanimaltesting.ThemethodshereindescribedforrapiddevelopmentofahighlyprotectiveSARSvaccineareequallysuitedtorapiddevelopmentofvaccinesagainstotherfatalhumancoronavirusinfections,e.g.,theMERScoronavirus
4、.KeywordsCoronavirus,SARS,MERS,Vaccine,Adjuvant,Deltainulin,Advaxadjuvant,Baculovirus,Manufacture,cGMP1IntroductionThesevereacuterespiratorysyndromecoronavirus(SARS)wasTrstidentiTedin2003afteraseriesoffatalpneumoniacaseschar-acterizedbyanin?ammatorycellinTltratewithdiffusealveolardam
5、age[1]startedinHongKongbeforespreadingtoothercoun-tries[2].Beforebeingcontrolledbyquarantinemeasures,~8000humanswereinfected,withfatalityashighas50%intheelderlyandanoverallcasefatalityrateof~10%[2].Morerecently,theMiddleEastrespiratorysyndromecoronavirus(MERS)hascausedaseriesofseriou
6、sand,insomecases,fatalhumaninfections[3].Giventheriskoffutureserioushumancoronavirusoutbreaks,developmentofasuitablevaccineplatformtoprotectagainstsuchvirusesisamajorpriority.Thesevaccinespresentseveralchallengesincludingtherapiditywithwhichtheseoutbreaksdevelopandhencetheneedforrapi
7、dvaccinemanufacture.Hence,asuccessfulcoronavirusvaccineplatformmustovercomemultiplechallenges.SunilThomas(ed.),VaccineDesign:MethodsandProtocols:Volume1:VaccinesforHumanDiseases,MethodsinMolecularBiology,vol.1403,DOI10.1007/978-1-4939-3387-7_14,?SpringerScience+BusinessMediaNewYork20
8、16269270Clif